



A clinical stage biotech informed by patient experience. Tackling unmet needs in neuroscience and mental health.

Company Secretary Change

Emyria Limited (ASX: EMD) (Emyria or the Company), data-backed drug development and care delivery company, advises that Ms Susan Park has been appointed Company Secretary of Emyria with effect from today upon Mr Simon Robertson's resignation.

Ms Park is a governance professional with over 25 years of experience in the corporate finance industry and extensive experience in Company Secretary and Non-Executive Director roles in ASX, AIM and TSX-listed companies.

Susan Park holds a Bachelor of Commerce degree from the University of Western Australia, majoring in Accounting and Finance; she is a Member of the Australian Institute of Chartered Accountants, a Fellow of the Financial Services Institute of Australian, and a Member of the Australian Institute of Company Directors.

She is also a Fellow of the Institute of Chartered Secretaries and Administrators and Chartered Secretaries Australia. Ms Park is Company Secretary of several ASX-listed companies.

Ms Susan Park will be responsible for communications with ASX concerning Listing Rule matters under ASX Listing Rule 12.6.

Release authorised by

Dr Michael Winlo, Emyria Managing Director


FOR FURTHER INFORMATION

Dr. Michael Winlo Managing Director +61 (0) 8 6559 2800 mwinlo@emyria.com Lexi O'Halloran Investor Relations +61 (0) 404 577 076 investors@emyria.com Andrew Williams
Media Relations
+61 (0) 412 614 125
awilliams@emyria.com

Sufian Ahmad Corporate Advisor +61 (0) 412 316 162 info@62capital.com.au



UPCOMING MILESTONES



ABOUT EMYRIA | emyria.com

Emyria Limited is a clinical drug development and care delivery company focused on accelerating drug development and improving patient outcomes in neuroscience and mental health via:

- **Drug Development:** Multiple, proprietary, Ultra-Pure cannabinoid dose forms suitable for registration against multiple indications. Emyria's first dose form, EMD-RX5, is in Phase 3 trials.
- **New Drug Discovery:** Inspired by MDMA, Emyria is developing one of the world's largest libraries of MDMA-like compounds with partner, the University of Western Australia.
- **Proprietary Real-World Data (RWD):** Emyria gathers robust and ethically-sourced data with patients cared for at Emyria's own specialist clinical service (Emerald Clinics). Emyria RWD can help support drug development and care model improvement.

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.